Bristol Myers Squibb

News

BMS immunotherapy combo approved in new colorectal use

Bristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients with advanced colorectal cancer.

News

NICE rejects BMS immunotherapy in advanced bladder cancer

No review for three years after final guidance

News

Roche to file Tecentriq in triple negative breast cancer

No other immunotherapies are approved in indication

News

EU regulators back BMS' Opdivo in new skin cancer use

Bristol-Myers Squibb’s cancer immunotherapy Opdivo is likely to gain another use in Europe after regulators recommended it after surgery for skin cancer.

Event coverage

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi

Views & Analysis

ASCO 2018 - Sunday 3rd June: Opdivo/Nektar, AbbVie's new leu...

Bristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from Nektar Therapeutics. But new early stage data from the cocktail pres

BMS immunotherapy combo approved in new colorectal use

NICE rejects BMS immunotherapy in advanced bladder cancer

Roche to file Tecentriq in triple negative breast cancer

EU regulators back BMS' Opdivo in new skin cancer use

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

ASCO 2018 - Sunday 3rd June: Opdivo/Nektar, AbbVie's new leu...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Bristol Myers Squibb

Editor's Picks